BioSpace News Archive

The COVID-19 research collaboration between Vir Biotechnology and GSK has largely come to an end, as Vir announced Monday it would be going it alone or with other partners.

The Pregnant Workers Fairness Act (PWFA) has been praised by many in the life sciences who see it as a step forward in protecting the rights of pregnant employees.

As biopharma executives sought funding last week at the BIO CEO & Investor Conference, the strategic mindset could be summed up in three words: flexibility, creativity and concession.

The FDA has rejected Soligenix’s NDA for HyBryte (synthetic hypericin), a therapeutic developed to treat early-stage cutaneous T-cell lymphoma.

Enveda’s primary R&D efforts will focus on inflammation, fibrosis and neurosensory biology within the GI, dermatology and pulmonary therapeutic areas.

Vivek Ramaswamy, the founder of Roivant Sciences, is officially running for president, the GOP hopeful announced Tuesday.

Fresh off of his Sanofi exit, John Reed is joining Johnson & Johnson, where he will serve as executive vice president, pharmaceuticals, R&D.

Valneva SE, a specialty vaccine company, announced that it completed enrollment and vaccination for a Phase 3 trial in adolescents, VLA1553-321, of its single-shot chikungunya vaccine candidate, VLA1553.

Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced its results for the financial year ended December 31, 2022.

Clover Biopharmaceuticals, Ltd. announced that the launch of its COVID-19 vaccine, a recombinant SARS-CoV-2 subunit vaccine, in the People’s Republic of China has begun with the first doses delivered and administered in Changxing, Zhejiang as part of China’s national second booster dose campaign targeting older adults, immunocompromised individuals and individuals with comorbidities.